A5002422862- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Medical Imaging and Pathology Studies
- Neonatal Respiratory Health Research
- Sarcoidosis and Beryllium Toxicity Research
- Tuberous Sclerosis Complex Research
- Eosinophilic Disorders and Syndromes
- Congenital Diaphragmatic Hernia Studies
- Inhalation and Respiratory Drug Delivery
- Pulmonary Hypertension Research and Treatments
- Chronic Obstructive Pulmonary Disease (COPD) Research
- Occupational and environmental lung diseases
- Mycobacterium research and diagnosis
- Radioactive contamination and transfer
- Occupational exposure and asthma
- Tuberculosis Research and Epidemiology
- Systemic Sclerosis and Related Diseases
- Respiratory and Cough-Related Research
- Respiratory Support and Mechanisms
- Lung Cancer Treatments and Mutations
- Pleural and Pulmonary Diseases
- Pneumonia and Respiratory Infections
- Histiocytic Disorders and Treatments
- Asthma and respiratory diseases
- Fatty Acid Research and Health
- Infectious Diseases and Mycology
National Kinki Chuo Hospital for Chest Disease
2016-2025
Fukujuji Hospital
2023-2024
Fujita Health University
2013-2024
Niimi College
2024
Universidad Autónoma de Madrid
2024
Assistance Publique – Hôpitaux de Paris
2023
Université Paris Cité
2023
Nationwide Children's Hospital
2023
Hôpital Cochin
2023
Isabela State University
2023
Nintedanib (formerly known as BIBF 1120) is an intracellular inhibitor that targets multiple tyrosine kinases. A phase 2 trial suggested treatment with 150 mg of nintedanib twice daily reduced lung-function decline and acute exacerbations in patients idiopathic pulmonary fibrosis.We conducted two replicate 52-week, randomized, double-blind, 3 trials (INPULSIS-1 INPULSIS-2) to evaluate the efficacy safety compared placebo fibrosis. The primary end point was annual rate forced vital capacity...
Section:ChooseTop of pageAbstract <<ContentsExecutive SummaryIntroductionMethodsSummary Major Revision...General Progress in IIPs ...Important Differential Di...Progress Specific IIPs...Rare IIPsRare Histologic PatternsUnclassifiable IIPClinical Classification o...BiomarkersReferencesCITING ARTICLES
This document provides clinical recommendations for the diagnosis of idiopathic pulmonary fibrosis (IPF). It represents a collaborative effort between American Thoracic Society, European Respiratory Japanese and Latin Society.The evidence syntheses were discussed formulated by multidisciplinary committee IPF experts. The was appraised formulated, written, graded using Grading Recommendations, Assessment, Development, Evaluation approach.The guideline panel updated diagnostic criteria IPF....
Preclinical data have suggested that nintedanib, an intracellular inhibitor of tyrosine kinases, inhibits processes involved in the progression lung fibrosis. Although efficacy nintedanib has been shown idiopathic pulmonary fibrosis, its across a broad range fibrosing diseases is unknown.
Background: This American Thoracic Society, European Respiratory Japanese and Asociación Latinoamericana de Tórax guideline updates prior idiopathic pulmonary fibrosis (IPF) guidelines addresses the progression of in patients with interstitial lung diseases (ILDs) other than IPF. Methods: A committee was composed multidisciplinary experts ILD, methodologists, patient representatives. 1) Update IPF: Radiological histopathological criteria for IPF were updated by consensus. Questions about...
With more than 900 000 confirmed cases worldwide and nearly 50 deaths during the first 3 months of 2020, coronavirus disease 2019 (COVID-19) pandemic has emerged as an unprecedented health care crisis. The spread COVID-19 been heterogeneous, resulting in some regions having sporadic transmission relatively few hospitalized patients with others community that led to overwhelming numbers severe cases. For these regions, delivery disrupted compromised by critical resource constraints diagnostic...
Lymphangioleiomyomatosis (LAM) is a progressive, cystic lung disease in women; it associated with inappropriate activation of mammalian target rapamycin (mTOR) signaling, which regulates cellular growth and lymphangiogenesis. Sirolimus (also called rapamycin) inhibits mTOR has shown promise phase 1-2 trials involving patients LAM.We conducted two-stage trial sirolimus 89 LAM who had moderate impairment--a 12-month randomized, double-blind comparison placebo, followed by observation period....
Section:ChooseTop of pageAbstract <<ContentsSummary Recommendation...IntroductionHow to Use These Guidelin...MethodsDefinitionClinical ManifestationsPathogenesisRadiological FeaturesHistopathological Feature...Diagnostic CriteriaDiagnostic InterventionsFuture DirectionsConclusionsReferencesCITING ARTICLES
The tuberculin skin test for immunologic diagnosis of Mycobacterium tuberculosis infection has many limitations, including being confounded by bacillus Calmette-Guérin (BCG) vaccination or exposure to nontuberculous mycobacteria. M. tuberculosis–specific antigens that are absent from BCG and most mycobacteria have been identified. We examined the use two these antigens, CFP-10 ESAT-6, in a whole blood IFN-γ assay as diagnostic BCG-vaccinated individuals. Because lack an accurate standard...
Section:ChooseTop of pageAbstract <<METHODSRESULTSDISCUSSIONAPPENDIXReferencesCITING ARTICLES
Section:ChooseTop of pageAbstract <<ContentsOverviewIntroductionMethodsQuestion 1: Should Patien...Question 2: 3: 4: VEGF-D...ConclusionsFuture DirectionsReferencesCITING ARTICLES
In the two replicate, placebo-controlled, 52-week, phase III INPULSIS trials, nintedanib 150 mg twice daily significantly reduced annual rate of decline in FVC, primary endpoint, subjects with idiopathic pulmonary fibrosis (IPF). It is unknown if this effect was uniform across all treated nintedanib.To investigate potential association demographic and clinical variables IPF.Subgroup analyses pooled data from trials were prespecified. Subgroups analyzed by sex, age (<65, ≥65 yr), race (white,...
Recommendations regarding key aspects related to the diagnosis and pharmacological treatment of lymphangioleiomyomatosis (LAM) were recently published. We now provide additional recommendations four specific questions LAM management pneumothoraces in patients with LAM.Systematic reviews performed then discussed by a multidisciplinary panel. For each intervention, panel considered its confidence estimated effects, balance desirable (i.e., benefits) undesirable harms burdens) consequences,...
A randomised, double-blind, phase II, dose escalation trial was conducted to assess the safety, tolerability and pharmacokinetics of tyrosine kinase inhibitor nintedanib, alone when added ongoing pirfenidone therapy, in Japanese patients with idiopathic pulmonary fibrosis. 50 were randomised receive nintedanib or placebo one three cohorts (nintedanib mg twice daily 100 for 14 days, 150 28 days). Patients receiving at inclusion stratified every group placebo. Adverse events reported nine out...
600 patients aged ≥18 years will be randomised in a 1:1 ratio to nintedanib or placebo. Patients with diagnosis of IPF excluded. The study population enriched two-thirds having usual interstitial pneumonia-like pattern on HRCT. primary endpoint is the annual rate decline forced vital capacity over 52 weeks. main secondary endpoints are absolute change from baseline King’s Brief Interstitial Lung Disease Questionnaire total score, time first acute lung disease exacerbation death and all-cause...
Introduction Nintedanib slows disease progression in patients with idiopathic pulmonary fibrosis (IPF) by reducing the rate of decline forced vital capacity, an adverse event profile that is manageable for most patients. We used data from six clinical trials to characterise safety and tolerability nintedanib investigate its effects on survival. Methods Data treated ≥1 dose 150 mg two times per day or placebo 52-week TOMORROW trial and/or open-label extension; INPULSIS their extension,...
Section:ChooseTop of pageAbstract <<IntroductionMethodsHistorical PerspectiveEpidemiologyEtiologiesClinical Manifestations a...Lung FunctionImaging FeaturesPathology FeaturesOutcome and ComplicationsPathogenesis Putative...Terminology Definitio...Is CPFE a Syndrome?ManagementClinical Trial Perspectiv...Relevance for the...Research PrioritiesConclusionsReferencesCITING ARTICLES
Rationale: A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis who received zinpentraxin alfa. Objectives: To investigate the efficacy and safety of alfa a III trial. Methods: This 52-week III, double-blind, placebo-controlled, pivotal was conducted at 275 sites 29 countries. Patients were randomized 1:1 to intravenous placebo or 10 mg/kg every four weeks. The primary endpoint absolute change from baseline Week 52 forced vital capacity....
KL-6, a mucin-like high-molecular-weight glycoprotein, is serum marker indicating the disease activity of pneumonitis, such as idiopathic pulmonary fibrosis (IPF), hypersensitivity and sarcoidosis. Immunohistochemical studies have shown that KL-6 strongly expressed on Type 2 pneumocytes also exists epithelial cells in other organs. It has not been clarified whether increased levels sera from patients with pneumonitis are derived lower respiratory tract. In this study, were evaluated...
Circulating interleukin-6 (IL-6) levels were determined using a sensitive enzyme immunoassay in adults with asthma stable condition during naturally occurring attacks and before after allergen inhalation tests. IL-6 was significantly elevated even asymptomatic asthmatic subjects (n = 17) compared normal control 17). During attacks, serum comparison those symptom-free (4 wk interval; n 8, p < 0.01). No significant difference observed obtained from the period 10). There elevation circulating...